Trial reportEuropean journal of nuclear medicine and molecular imaging2026
Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [
Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer-associated fibroblasts in therapeutic resistance of hepatocellular carcinoma: evidence, mechanisms, and translational implications.Medical oncology (Northwood, London, England) · 2026Review
- Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.Cancer cell · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeHepatocellular carcinoma (HCC) commonly develops in the setting of cirrhosis, highlighting the need for reliable noninvasive biomarkers to assess both tumor burden and hepatic function. Conventional [18F]FDG PET/CT has limited sensitivity for HCC. In contrast, FAPI PET/CT targets fibroblast activation protein (FAP), enabling visualization of cancer-associated fibroblasts (CAFs) and stromal fibrosis, and offering a novel imaging strategy for HCC.
methodsIn this prospective single-center study, 57 HCC patients underwent [18F]AlF-NOTA-FAPI-04 PET/CT. Quantitative tumor variables included SUVmax, SUVmean, metabolic tumor volume, and total lesion FAP expression (TLF). Total liver segmentation yielded the Total liver SUVmean (TSUVmean) and Total liver FAP expression (TTLF); Boolean operations were used to derive background metrics (BSUVmean, BTLF). Associations with Child–Pugh score, FIB-4 fibrosis index, alpha-fetoprotein (AFP), tumor size, portal vein tumor thrombosis (PVTT), and CAF immunohistochemical markers were analyzed. Prognostic value of imaging and clinical variables was assessed by Kaplan–Meier analysis, Cox regression, and a nomogram.
resultsSUVmean and TTLF were associated with Child–Pugh score, tumor burden, and liver dysfunction. Patients with higher SUVmean (≥ 6.32) or TTLF (≥ 3226.31) had shorter progression-free and overall survival, and TTLF remained an independent predictor (P = 0.02). Our nomogram integrating imaging and clinical variables showed good discrimination (AUC = 0.875, 95% CI 0.733–1.000). Background uptake reflected fibrosis severity, as patients with FIB-4 grade ≥ 3.25 had higher TTLF and BTLF. FAPI uptake correlated with FAP immunohistochemical staining and intratumoral fibrosis, suggesting that it may serve as a noninvasive surrogate of tumor stromal activity.
conclusion[18F]AlF-NOTA-FAPI-04 PET/CT provides an integrated assessment of tumor activity, CAF activation, and hepatic fibrosis in HCC. SUVmean and TTLF are robust prognostic biomarkers and background uptake captures fibrosis severity, supporting its role as a noninvasive tool for risk stratification and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.